Cell and Gene Therapy Manufacturing QC Market is Expected to Drive Growth at a CAGR of 22.80% between 2020 and 2030

The global cell and gene therapy manufacturing QC market held a value of $574.8 million. The market is expected to grow at a CAGR of 22.80% during the forecast period 2020-2030 and attain a value of $5.92 billion by 2030. The growth in this market is primarily attributed to the rise in prevalence of cancer and chronic diseases and increase in investment from big pharma companies. In addition, the entry of several established players from the biomanufacturing market, such as Lonza AG and Merck KGaA, as well as diversification of product and service offerings among analytical testing juggernauts such as Charles River Laboratories International, Inc. and Eurofins Scientific SE, is aiding in tremendous market growth.

Market Segmentation

• Product – Services and Products (Kits and Assays, Instruments, Reagents, and Software)

• Process – Starting Material Preparation, Upstream Processing, and Downstream Processing

• Analytical Methods – Safety Testing, Purity Testing, Potency Testing, Identity Testing, and Stability Testing

• Technology – Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), and Electrophoresis, among others

Regional Segmentation

• North America – U.S., and Canada

• Europe – Germany, U.K., France, Italy, Spain, Netherlands, Russia, and Rest-of-Europe

• Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

• Latin America – Brazil, Mexico, and Rest-of-Latin America

• Rest-of-the-World

Growth Drivers

• Increasing Prevalence of Cancer and Chronic Diseases

• Rising Number of Clinical Trials

• Steady Investment and Consolidation in the Cell and Gene Therapy Market

• Favorable Regulatory Environment

Market Challenges

• Lack of Reliable Vector Production for Cell and Gene Therapy

• Lack of Therapy Specific Assays

Market Opportunities

• Drug Approvals and Strong Pipeline of Cell and Gene Therapies

• Multiple Investments in Expansion of cGMP Units

Key Companies Profiled

bioMérieux SA, Bio-Techne Corporation, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific S.E., F. Hoffmann-La Roche Ltd., Intertek Group plc, Lonza Group AG, Merck KGaA, Sartorius AG, SGS S.A, Thermo Fisher Scientific Inc., WuXi AppTec, Sistemic Scotland Limited, and Vigene Biosciences, Inc.

Request a Sample - https://bisresearch.com/requestsample?id=1071&type=download

Comments

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Digital PCR Market size,Share, Leading Players, Growth, Development and Demand Forecast to 2032

Increasing investments in R&D for d-PCR molecular diagnostics is one of the major opportunities in the global digital PCR market. Several biotechnology and life sciences companies are working collaboratively on diagnostic test development and using d-PCR as a therapeutic means for applications in several disease indications to enable efficient diagnosis, treatment selection, and treatment monitoring. The global digital PCR market is projected to reach $2,847.8 million by 2032 from $441.2 million in 2021, at a CAGR of 18.73% during the forecast period 2022–2032. The growth in the global digital PCR market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases globally, the rising awareness of d-PCR-based diagnostic testing, and the significant number of funding for executing research and development. Impact of COVID-19 The current global digital PCR market comprises kits and assays, system, and reagents and consuma...

Radiation Dose Management Market Likely To Increase Size, Shares, And Demand Forecast 2022-2032

Radiation dose is the amount of radiation absorbed by a patient during a diagnostic imaging procedure. A large dose of radiation can cause tissue damage and increase the risk of developing cancer in later stages of life.The development of on-cloud dose management solutions and the growing initiatives on radiation dose management for pediatric procedures are some of the major opportunities in the global radiation dose management market. Furthermore, some of the key trends going on in the market include the increasing development of imaging modalities with technologies that lower radiation dose, partnerships and strategic business alliances dominating the market, and various collaborations among market players. The global radiation dose management market was valued at $212.8 million in 2021 and is anticipated to reach $586.7 million by 2032, witnessing a CAGR of 10.30% during the forecast period 2022–2032. The growth in the global radiation dose management market is ex...

Market Research Reports

Search This Blog